Shares of Sequenom (SQNM) are down 32% premarket following Wednesday evening's Q2 report....

|By:, SA News Editor

Shares of Sequenom (SQNM) are down 32% premarket following Wednesday evening's Q2 report. Investors are nervous about comments the company made regarding delays in test payments. For more, see the Q&A on the conference call, notably the back and forth between management and Jefferies' Brandon Couillard. (transcript)